Ovid Therapeutics Inc (OVID) - Long-Term Liabilities to Capital
The stability of Ovid Therapeutics Inc. (OVID) is confirmed by the implementation of ESG standards and bioethics in drug development. The ratio of long-term debt to net assets visualizes financial resilience, where 0.05 reflects the latest value of the metric. The operational basis relies on the creation of a unique ecosystem for pediatric epilepsy therapy, while the humanitarian status of healthcare shields the company's scientific process from geopolitical risks.
&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_OVID_-_Ovid-Therapeutics-Inc._-_Long-Term-Debt-to-Equity-Ratio "OVID - Ovid Rx Long-Term Debt to Capital over the range 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Ovid Therapeutics Inc.
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Capital Ovid Therapeutics Inc.|OVID - Long-Term Debt to Equity|Current Liabilities to Capital Ovid Rx|OVID - Company Total Debt|Debt to Book Capitalization Ratio Ovid Therapeutics Inc.|OVID - Company Long-Term Debts|Short-Term Debt Volume Ovid Therapeutics|Immediate Liquidity Ratio ovidrx.com
- net income and valuation ratios data:
General company analysis:ovidrx.com
Developing orphan drugs requires colossal R&D investments to overcome FDA regulatory barriers. The current long-term debt-to-equity trend for Ovid Therapeutics Inc. (OVID) reflects the proportion of long-term liabilities relative to the company's equity. This metric allows for an assessment of financial leverage and the stability of the funding structure. An increase in this ratio signals a growing credit burden for the sake of expansion, while a low value confirms capital autonomy and the minimization of default risks.
Key competitors
Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|Long-Term Debt to Equity Denali Therapeutics|Long-Term Liabilities to Capital harmonybiosciences.com HRMY|Long-Term Debt to Equity Ratio BHVN (Biohaven)|Long-Term Debt to Equity AMLX (Amylyx Pharmaceuticals Inc)|Long-Term Debt to Capital TRVI (Trevi Pharma)|Ratio of Long-Term Indebtedness to Capital Praxis Corp (PRAX)|Anavex Life Sciences - Long-Term Debt to Capital|CBLL (ceribell.com) - Long-Term Debt to Capital Ratio|PRTA (Prothena Corp) - Long-Term Debt to Equity Ratio|Alector - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio ANNX|OMER (Omeros Corp.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital NGNE|ACIU (acimmune.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|Neumora (NMRA) - Long-Term Liabilities to Capital|SCLX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient TVGN (Tevogen Bio Inc.)|ACOG: Long-Term Debt to Capital|cogrx.com (CGTX) - Long-Term Debt to Capital|Long-Term Debt to Equity Inhibikase Therapeutics, Inc.|Cassava Sciences Inc - Long-Term Liabilities to Equity|Long-Term Debt to Capital ASRT|COYA - Long-Term Liabilities to Capital|Vistagen - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acumenpharm.com ABOS|CRVO: Long-Term Debt to Equity Ratio|Alterity Therapeutics - Long-Term Loans to Capital Ratio|CLNN: Long-Term Debt to Capital|PEPG - Ratio of Long-Term Indebtedness to Capital|JUNS (Jupiter Neurosciences Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio relmada.com (RLMD)|Long-Term Debt to Equity Annovis Bio (ANVS)|Ratio of Long-Term Indebtedness to Capital gracetx.com|Firefly Neuroscience Inc - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient KLTO|NeuroSense Therapeutics, Ltd. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital revivapharma.com RVPH|metaviatx.com (MTVA) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio NRXS|HSDT (Helius Medical Technologies, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Passage Bio Corp (PASG)|Long-Term Debt to Equity Ratio NEUP (Neuphoria Therapeutics Inc.)|Ratio of Long-Term Indebtedness to Capital minervaneurosciences.com|Long-Term Debt to Equity Athira Pharma ATHA|Addex Therapeutics Ltd. (ADXN) - Long-Term Liabilities to Capital|ALZN: Long-Term Debt to Equity Ratio|CYCN: Long-Term Debt to Equity|PTIX: Long-Term Debt to Capital|KTTA - Ratio of Long-Term Indebtedness to Capital|CRGT (Cortigent Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio ATXI (Avenue Therapeutics Inc.)|Long-Term Debt to Equity Brainstorm Cell Therapeutics, Inc. (BCLI)|Cara Therapeutics Inc - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital CHRO (Chromocell Therapeutics)|Eliem Therapeutics, Inc. (ELYM) - Long-Term Liabilities to Capital|ITCI: Long-Term Debt to Equity Ratio|LBPH - Long-Term Debt to Capital|Marinus (MRNS) - Long-Term Debt to Equity|NKGen Biotech Corp - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity NeuroBo Pharmaceuticals|Long-Term Liabilities to Capital sagerx.com SAGE|Long-Term Debt to Equity Synaptogenix (SNPX)|TRVN - Long-Term Liabilities to Capital|Vigil Neuroscience, Inc. - Long-Term Debt to Equity Ratio|Anew Medical Inc. - Long-Term Debt to Equity|Cerevel Therapeutics - Long-Term Debt to Capital